Completed NA INTERVENTIONAL 2-arm NCT03908528

Alpha-Lipoic Acid in Breast Cancer Patients

Role of Alpha-Lipoic Acid Against Chemotherapy Induced Toxicities in Breast Cancer Patients

Sponsor: Damanhour University

Conditions Breast Cancer Chemotherapeutic Toxicity

Interventions Alpha-lipoic acid Plus Chemotherapy (doxorubicin (also known as Adriamycin) plus cyclophosphamide followed by taxol) Placebo Plus Chemotherapy (doxorubicin (also known as Adriamycin) plus cyclophosphamide followed by taxol)

Updated 10 times since 2019 Last updated: Oct 4, 2021 Started: Mar 1, 2019 Primary completion: Oct 30, 2020 Completion: Oct 30, 2020

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03908528, this NA trial focuses on Breast Cancer and Chemotherapeutic Toxicity and remains completed. Sponsored by Damanhour University, it has been updated 10 times since 2019, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

10 versions recorded

Sep 2024 — Present [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Nov 2021 — Jul 2024 [monthly]

Completed NA
Apr 2021 — Nov 2021 [monthly]

Completed NA
Mar 2021 — Apr 2021 [monthly]

Completed NA

▶ Show 5 earlier versions

Feb 2021 — Mar 2021 [monthly]

Completed NA

Status: Recruiting → Completed
Jan 2021 — Feb 2021 [monthly]

Recruiting NA
Jan 2020 — Jan 2021 [monthly]

Recruiting NA
Oct 2019 — Jan 2020 [monthly]

Recruiting NA
May 2019 — Oct 2019 [monthly]

Recruiting NA

First recorded

Mar 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Damanhour University

Data source: Damanhour University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Tanta, Egypt